Methods of treating age related disorders

Abstract

The invention generally relates to methods of treating a patient having, and/or at risk of, oxidative distress disorders and/or age-related disorders. The disclosure also generally relates to methods of treating memory impairment or enhancing the cognitive function of a patient in need thereof. Such methods may include administering a therapeutically effective amount of a MetAP2 inhibitor.

What is claimed is: 
     
         1 - 7 . (canceled) 
     
     
         8 . A method of treating an age-related neuromuscular disorder in a patient in need thereof, comprising administering to the patient an effective amount of an irreversible MetAP2 inhibitor that covalently binds to MetAP2 , wherein said inhibitor, upon administration increases the level of metabolic products formed in the citric acid cycle and does not substantially increase alphaketoglutarate in the liver of said patient. 
     
     
         9 . (canceled) 
     
     
         10 . The method of  claim 8 , wherein said patient exhibits a reduction in expression of mCLK1. 
     
     
         11 . The method of  claim 8 , wherein the patient, upon administration of the MetAP2 inhibitor, exhibits a decrease in non-mitochondrial oxidative damage. 
     
     
         12 . The method of  claim 8 , wherein the patient, upon administration of the MetAP2 inhibitor, exhibits increased mitochondrial oxidative stress. 
     
     
         13 . The method of  claim 8 , wherein said therapeutically effective amount does not substantially modulate or suppress angiogenesis. 
     
     
         14 . The method of  claim 8 , further comprising administration of the MetAP2 inhibitor until a marker level is returned to a normal range. 
     
     
         15 . The method of  claim 14 , wherein the marker is C-reactive protein. 
     
     
         16 . A method of decreasing the rate of development of one or more markers indicative of aging in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a MetAP2 inhibitor, wherein the marker indicative of aging is an oxidative biomarker or C-reactive protein. 
     
     
         17 - 22 . (canceled) 
     
     
         23 . The method of  claim 8 , wherein said MetAP2 inhibitor is administered parenterally or non-parenterally. 
     
     
         24 . (canceled) 
     
     
         25 . The method of  claim 16 , wherein the MetAP2 inhibitor is a fumagillin analog. 
     
     
         26 . The method of  claim 25 , wherein the MetAP2 inhibitor is administered at a dose of about 0.01 mg/kg to about 10 mg/kg. 
     
     
         27 . The method of  claim 25 , wherein the MetAP2 inhibitor is administered at a dose of about 0.04 mg/kg to about 1.0 mg/kg.